Biallelic Knockout of CTLA4

The USPTO published a patent application (US20260091113A1) disclosing compositions comprising RNA molecules with guide sequences for biallelic knockout of CTLA4. The application covers 4,891 sequence variants (SEQ ID NOs: 1-4891) and methods of use thereof. The CPC classifications indicate applications in genetic engineering, molecular therapeutics, and pharmaceutical compositions.

Companies engaged in CRISPR-based gene editing, immune checkpoint therapies, or CTLA4-targeted development should review this application as potential prior art for freedom-to-operate assessments. No compliance obligations or deadlines arise from this publication. Patent applications impose no immediate obligations on third parties; the ultimate scope of any granted patent claims will be determined during prosecution.